They aren't just "pandemic stocks." ...

In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk melanoma, while the FDA granted expedited review and an August 5, 2026 ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company’s value has increased by approximately $1.2 billion over ...

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Shares of Moderna MRNA rose about 4% on Friday after the company announced that the EMA’s Committee for Medicinal Products ...

CHONGQING, CHINA - FEBRUARY 3: In this photo illustration, a smartphone displays the logo of Moderna, Inc. (NASDAQ: MRNA), a U.S.-based biotechnology company specializing in messenger RNA (mRNA) ...

Moderna Inc MRNA shares are rising in Tuesday’s after-hours session after the company announced it reached a settlement agreement with Arbutus Biopharma and Genevant Sciences. Moderna shares are ...